Amsokigene autoleucel (amsoki-cel) is an engineered autologous tumor-infiltrating lymphocyte (TIL) therapy designed to express membrane-bound interleukin-15 (mbIL15) under pharmacologic control by acetazolamide (ACZ). The therapy targets advanced melanoma resistant to immune checkpoint inhibitors (ICI). Early results from two combined clinical trials—a first-in-human (FIH) single-center phase 1 and a multicenter phase 1/2 trial called Agni-01—have been analyzed to evaluate safety, tolerability, and preliminary efficacy.
During the FIH study, the initial patient treated experienced a rapid expansion of lymphocytes and vasogenic edema in a previously irradiated brain metastasis, prompting the study team to revise the protocol. These modifications involved an 80% reduction in the maximum dose of amsoki-cel and a 75% reduction in ACZ dosing. After establishing safety at these lowered doses, doses were gradually increased in the FIH study and then re-escalation began in the Agni-01 trial.
Across the pooled sample of 37 patients (17 from FIH and 20 from Agni-01), no dose-limiting toxicities, requirement for intensive care unit treatment, or treatment-related deaths were reported. The study team identified the recommended phase 2 dose (RP2D) based on the overall safety profile and preliminary anti-tumor activity observed during phase 1.
Treatment-emergent adverse events (TEAEs) of grade 3 or higher mostly involved hematologic abnormalities. Neutropenia was the most common severe adverse event, occurring in approximately 65% of the patients, followed by leukopenia and lymphopenia each affecting 57%. Anemia and thrombocytopenia each affected around 38% of study participants at grade 3 or higher severity.
Serious TEAEs were documented in 10 patients total, evenly divided between hematologic and non-hematologic categories. These events were reported in about 27% of the overall cohort. The study’s authors noted that no unexpected toxicities emerged during dose escalations, and the safety profile was comparable to expectations for TIL therapies while avoiding the high toxicities associated with systemic IL-2 administration.
The Agni-01 phase 2 portion evaluated objective response rate (ORR) at the RP2D. Out of nine evaluable patients, six achieved an objective response, translating to an ORR of 66.7%. Including six phase 1 patients treated at RP2D, a total of 15 subjects formed the efficacy evaluable population (Key Efficacy Set). Within this group, 66.7% (10 patients) achieved objective responses, which included two complete responses.
These findings suggest potentially beneficial anti-tumor activity of amsoki-cel in a heavily pretreated advanced melanoma population with ICI resistance. However, the authors emphasize that these preliminary results require validation in larger cohorts and longer follow-up.
Amsoki-cel leverages a novel pharmacologic regulation system whereby mbIL15 is fused to an acetazolamide (ACZ)-responsive domain (DRD) derived from a mutated carbonic anhydrase-2 gene. Under basal conditions, this fusion protein undergoes proteasomal degradation due to misfolding, preventing IL-15 signaling. Administration of ACZ stabilizes the DRD and enables surface expression of mbIL15, which supports T-cell expansion and persistence without requiring exogenous interleukin-2.
This approach aims to overcome limitations observed with non-engineered TIL therapies, which depend on high-dose systemic IL-2 with significant toxicities and complex lymphodepletion regimens. By enabling controlled IL-15 expression, amsoki-cel may achieve TIL expansion and tumor targeting while mitigating systemic side effects.
While the pooled analyses show encouraging safety and early efficacy signals, the data have limitations including small patient numbers and relatively short follow-up durations. The exact dosing schedules, long-term persistence of engineered TILs, durability of responses, and comparative outcomes versus existing therapies remain undefined in these early-phase trials.
A pivotal, separate phase 2 cohort within the Agni-01 trial is ongoing, aiming to further elucidate efficacy and safety profiles. Future analyses will be essential to establish the clinical utility of amsoki-cel as a therapeutic option for patients with advanced ICI-resistant melanoma. The trials are registered under ClinicalTrials.gov identifiers NCT05470283 and NCT06060613.